Review

Functional glycomics and evidence for gain- and loss-of-functions of target proteins for glycosyltransferases involved in N-glycan biosynthesis: their pivotal roles in growth and development, cancer metastasis and antibody therapy against cancer

By Naoyuki Taniguchi,†) Jianguo Gu, Motoko Takahashi, and Eiji Miyoshi

Department of Biochemistry, Osaka University Graduate School of Medicine
2-2, Yamadaoka, Suita, Osaka 565-0871
(Communicated by Tamio Yamakawa, M. J. A., Feb. 12, 2004)

Abstract: N-Acetylglucosaminyltransferase V (GnT-V), N-acetylglucosaminyltransferase III (GnT-III) and α1-6 fucosyltransferase (Fut8) catalyze reactions that form biologically important branching N-linked sugar chains in glycoproteins. The above three branching N-glycan sugar chains, β1-6 GlcNAc branching, bisecting GlcNAc and core fucose (α1-6 fucose), play major roles in cancer invasion and metastasis, the inhibition of cancer metastasis, and antibody-dependent cellular cytotoxicity (ADCC), growth and development, respectively. A functional glycomic approach identified the gain- and loss-of-functions of glycoproteins as the result of the aberrant glycosylation. A membrane-type metal dependent serine proteinase designated matriptase which contains β1-6 GlcNAc branching became resistant to auto-digestion and proteolysis by trypsin, and resulted in a constitutively active form which might be implicated in cancer invasion and metastasis. GnT-V also acts as an angiogenic factor without the mediation of functions as a glycosyltransferase. Recently, a GnT-V homologue, GnT-IX has been identified. This gene is expressed at relatively high levels in the brain and acts on N-glycans to form a unique branched structure, as well as O-mannosyl glycans. The addition of bisecting GlcNAc to various signaling molecules or adhesion molecules suppresses cancer metastasis. Fut8 knock-out mice, due to the lack of a core fucose (α1-6 fucose) in target glycoproteins, show disorders in growth and development. The presence of a bisecting GlcNAc or the absence of a core fucose in IgG molecules enhances ADCC activity for killing tumor cells by up to 10 to 100 fold and therefore is thought to have considerable use in antibody therapy against cancer. These data clearly indicate that gain- and loss-of-functions of target proteins for these glycosyltransferases are biologically important.

Key words: Remodeling of sugar chains; glycosyltransferase; gain- and loss-of-functions; cancer metastasis; growth and development; antibody therapy.

Introduction. The post genomic era, after completion of the sequencing of the human genome and that of many other species, has opened new avenues for our understanding of the genome net-work including interactions of protein-protein and protein-DNA, structure and function of proteins, and the post-translational modification of proteins which may be directly linked to certain diseases. It is well known that a large number of proteins undergo posttranslational modifications with corresponding changes to their structure and function. Among the various posttranslational modification reactions of proteins, glycosylation is the most abundant, nearly 50% of all proteins are considered to be glycosylated.1) Glycosylation reactions are catalyzed by the catalytic action of glycosyltransferases and sugar chains are added to various complex carbohydrates such as glycoproteins, glycolipids and proteoglycans.2) Sugar chains play an important role in cell growth, cell-
cell interactions, cancer metastasis, development, differentiation, and immune reactions. A large number of glycosyltransferases have been cloned and some of their important functions are now understood. Fringe is a glycosyltransferase that regulates Notch signaling and the mutation of β1-2 N-acetylglucosaminyltransferase (POMGnT1) results in Muscle Eye Brain disease. Various congenital disorders of glycosylation (CDG) are due to the mutation of glycosyltransferases or related genes and various glycosyltransferase gene KO mice have been developed. To identify the actual target proteins that may be directly related to the cause of the diseases is an important issue because phenotypic changes or symptoms of CDG patients are sometimes not a direct consequence of glycosyltransferase gene deletion or mutations but an indirect consequence due to the aberrant glycosylation of target glycoproteins or complex carbohydrates. In this context, our goal is to identify target proteins that carry a specific sugar chain by using sugar remodeling techniques and functional glycomics.

This review summarizes the gain- and loss-of-functions of branching sugar chains produced by three glycosyltransferases that are involved in N-linked glycan biosynthesis.

**Purification of glycosyltransferases and the cloning of their genes.** The authors’ group has been interested in tumor-associated changes in glycoproteins such as γ-glutamyltranspeptidase which plays a major role in the biosynthesis of glutathione and found that the bisecting GlcNAc residues are found in enzymes purified from ascites hepatoma AH-66 but not in enzymes purified from normal rat livers. In order to confirm the mechanism that controls the appearance of the bisecting GlcNAc residues in the enzymes purified from tumor cells and to identify the specific glycosyltransferase responsible for producing the bisecting GlcNAc, we developed assay methods for various glycosyltransferases including N-acetylglucosaminyltransferases III, IV and V using pyridylaminated sugar chains as an acceptor substrate. This assay method, which is simple and reproducible, permitted the assay of enzyme activities on a small scale and was suitable for use during the purification of unstable enzymes. Using this method, we successfully purified GnT-III, by affinity chromatography using an acceptor substrate as a ligand. After obtaining partial amino acid sequences, we were able to clone the cDNA for GnT-III. Subsequently, this strategy was applied to the other enzymes such as GnT-V, GnT-IV, the central type I synthetic enzyme, and α1-6 fucosyltransferase (Fut8) (Fig. 1). All these enzymes have essentially few sequence homologies with each others, therefore it was necessary to purify the enzyme proteins to obtain partial amino acid sequence data and to clone the cDNAs. Here we demonstrate some new functions of sugar chains by a sugar remodeling technique using above cloned glycosyltransferase genes.

**Gain-of-function of GnT-V.** The β1-6 GlcNAc branching structure acquires the properties of cancer invasion and metastasis. Five glycosyltransferase genes cloned by our group have a type II transmembrane topology and are tightly bound to the Golgi apparatus.

![Fig. 1. Five glycosyltransferases (underlined) purified by our group and for which their genes were cloned. These enzymes determine the branching structure of N-linked sugar chains that will be further biosynthesized. GnT-I and GnT-II were purified and their genes were cloned by other groups. In this review we focus mainly on the three enzymes such as GnT-III, GnT-V, and Fut8.](image-url)
Their genes have multiple promoters and are expressed in an organ and tissue-specific manner.2 Various glycosyltransferases provide sugar chains with structural diversity. The relation between GnT-V and cancer metastasis has been reported by Dennis et al.28 and Yamashita et al.29 as judged by lectin reactivity and structure analyses. Our group also reported on the up-regulation of GnT-V in the liver of a rodent model of hepatocarcinogenesis as well as regenerative liver.30,31 However, the mechanism by which glycosyltransferase genes are regulated remains unclear. We reported on the direct implication of a transcription factor, Ets-1, in the underlying mechanism of the gene expression of GnT-V in various cancer cell lines32-34 and up-regulation of GnT-V by TGF-β35 or Her2/neu was also reported.36 The level of GnT-V mRNA in human hepatoma tissues is correlated well with that of Ets-1 mRNA. A dominant negative form of Ets-1 was reported to suppress GnT-V expression.34 These data confirm that the GnT-V gene is generally regulated by Ets-1. It has recently been reported that several glycosyltransferase genes are regulated by Ets-1 and some other glycosyltransferases appear to be regulated by a similar mechanism. These results may provide a new route for elucidating the mechanism of cancer metastasis via Ets-1.

A different type of underlying mechanism for cancer metastasis may be operative but the acquisition of β1-6 GlcNAc branching of a specified glycoprotein(s) may cause functional changes in metastatic potential.37-39 We established a gastric cancer cell line which overexpressed GnT-V and identified a matriptase, a membrane type metal dependent serine proteinase, as a target glycoprotein of GnT-V.40,41 The matriptase was independently cloned by two groups and shown to be involved in cancer progression, invasion and metastasis.32,43 Matriptase is also involved in the activation of hepatocyte growth factor (HGF) and tissue plasminogen activator.44 It has 4 potential N-glycosylation sites, and one of which, Asn 772 is the actual target amino acid residue for glycosylation by GnT-V as evidenced by site-directed mutagenesis.41 Asn 772 is conserved only in family members of serine proteinases such as trypsin etc. Matriptase in which β1-6 GlcNAc branching is added by GnT-V was found to be resistant to auto-digestion by itself as well as exogenously added trypsin. Thus, the aberrant glycosylation of matriptase by GnT-V at N-glycosylation sites such as Asn 772 led to a constitutively active form of this proteinase and this may enhance susceptibility to cancer invasion and metastasis.

We have also found that GnT-V is a bifunctional protein and functions as a glycosyltransferase as well as an angiogenic releasing factor.45 GnT-V has a heparin binding domain, KRRKKK which is very similar to that of other angiogenic factors. Deletion mutants of GnT-V which lack catalytic activity showed angiogenic activity which can be attributed to its competitive binding to certain proteoglycans with FGF2, indicating that the angiogenic factor releasing properties of GnT-V is not involved in its catalytic properties. Moreover we found that GnT-V is cleaved by proteinase(s) including γ-secretase and then released as a soluble form, which acts as an angiogenic releasing factor.

Very recently our group identified a new enzyme designated GnT-IX, a β1-6 N-acetylglucosaminyltransferase, a homolog of GnT-V, as shown in Fig. 1.46 Subsequently Pierce’s group also reported on the same enzyme.47 Our group showed that GnT-IX also acts on O-mannosylglycans.48 This report is very important because the enzyme is specifically expressed in the brain and testis. Moreover, there is an enzyme designated POMGnT-1 which catalyses the addition of β1-2 GlcNAc to O-mannosylglycan and the mutation of which causes MEB (muscle eye brain) disease due to an impairment in the glycosylation of α dystroglycans.49-50 Even though GnT-IX is not expressed in muscle tissues, the lack of GnT-IX may be implicated in the neuropathy and the development of KO mice of GnT-IX may answer the question of whether this enzyme is involved in some types of brain or neural diseases.

**Gain-of-function of GnT-III: bisecting GlcNAc has anti-metastatic function.** We hypothesized that the suppression of β1-6 GlcNAc branching by the inhibition of GnT-V activity would be possible, based on substrate specificity studies. Since GnT-III and GnT-V act on the same substrate but once GnT-III acts on the substrate first and produces a bisecting GlcNAc structure,50 GnT-V is not able to act further. We therefore assumed that this may lead to a suppression of metastatic potential in vivo. Computer modeling of these reactions provided support for the above hypothesis.50 Based on these analyses, we transfected the GnT-III gene into melanoma B16F1 cells with a high metastatic potential, and attempted to remodel the sugar chains. When the GnT-III gene-transfected melanoma cells were injected into syngeneic mice via the tail vein, lung metastasis was minimal51 whereas many lung metastatic foci were observed in mock-transfected melanoma cells. Sugar analyses by lectin blotting of the cells indicated that the β1-6 GlcNAc branching structures originally found in the parental cells were no
longer present in the GnT-III transfectants. Moreover, some of the glycoproteins in the GnT-III transfectants would be expected to be functionally modified as judged by cell biological parameters such as cell adhesion and cell invasion capacity. Among those molecules, E-cadherin a homophilic type of adhesion molecule

which is highly associated with the prevention of metastasis was aberrantly glycosylated in the GnT-III gene transfectants. The E-cadherin on cell surfaces was found to be resistant to proteolysis and remained on the cell-cell borders as result of sugar remodeling. As a result of these changes, cancer cells with metastatic potential were not able to be detached from the cells to proceed to the metastatic machinery. We also found that the glycosylation of E-cadherin leads to a reduced level of phosphorylation of β-catenin by EGFR (EGF-receptor) or src signaling and therefore β-catenin maintains a tight complex with E-cadherin and is not translocated into the nuclei. Moreover, β-Catenin otherwise enhances various gene expressions that are related to cell growth or oncogenesis. Suppression of the phosphorylation of β-catenin, therefore, permits it to remain on the cell surface and not to be released from the complex and this may also enhance the homophilic interactions of E-cadherin and contribute to the suppression of cancer metastasis.

Transfection of the GnT-III gene also results in the alteration of functions of growth factor receptors. The authors' group, in collaboration with the Moskal group, found that GnT-III modulates the functions of epidermal growth factor receptors. Moreover, GnT-III modification of EGFR enhances mitogen-activated protein (MAP) kinase activity. This may lead to biological changes in processes such as cell growth and apoptosis. On the other hand, regarding growth factors, it is known that nerve growth factor facilitates the differentiation of PC12 cells into neurite cells. An overexpression of the GnT-III gene in PC12 cells resulted in the addition of a bisecting GlcNAc to Trk A, a nerve growth factor (NGF) receptor, and even when NGF was added to the cells, the dimerization of the receptor was inhibited and the signaling for differentiation was suppressed. Moreover, an Asn420Gln mutant of the EGF receptor resulted in the spontaneous oligomerization and activation of the receptor, both in the presence and absence of the EGF ligand.

More recently Shibukawa et al. reported that the transfection of GnT-III in Hela cells suppresses H2O2-induced activation of the PKCδ-JNK pathway, resulting in the inhibition of apoptosis. These lines of evidence indicate that bisecting GlcNAc is capable of gaining function in terms of intracellular signaling.

**Loss-of-function of Fut8: growth retardation due to the lack of a core fucose.** Fut8 catalyzes the transfer of a fucose residue from GDP-fucose to position 6 of the innermost GlcNAc residue of the hybrid and complex types of N-linked oligosaccharides on glycoproteins. The gene that encodes this enzyme was designated Fut8. The enzyme was first purified to homogeneity and cloned by our group from porcine tissue as well as from human gastric cancer cells. The deletion of the Fut8, brought about marked phenotypic changes of mice. Namely, 60% of the mice died during the neonatal period and the remainder died within 3 weeks. The mice suffered from lung emphysema. An examination of respiratory capacity indicated that Fut8 KO mice that had been exposed to hypercapnea or hypoxia had an extremely low ventilation capacity, compared to heterozygous or normal control mice. It has been reported that there are several causes which may lead to lung emphysema. The overexpression of platelet-derived growth factor (PDGF), matrix metalloproteinase (MMPs) -1, -2, -9 and -12 has been reported to be causes of human lung emphysema. Interestingly, in Fut8 KO mice, the expression levels of some MMPs were aberrantly up-regulated, while tissue inhibitors of metalloproteinases (TIMPs) were down-regulated, suggesting that imbalanced-metabolism of extracellular matrix occurred in the lung of KO mice. MMP genes are usually positively or negatively regulated by cytokines such as IFN-γ, TNF-α and IL-13 or TGF-β signaling, respectively. Namely, IL-13 and IFN-γ up-regulate MMP gene expression via JAK and STAT signaling whereas TGF-β down-regulates the gene expression of MMPs via the TGF-β receptor and smad proteins (Fig. 2). Therefore, it would be interesting to determine whether the α1-6 fucosylation of membrane receptors regulates their biological functions.

**Gain-of-function of bisecting GlcNAc and core fucose in the ADCC activity.** Natural Killer (NK) cells are defined by their ability to kill cells that display a foreign antigen such as tumor cells regardless of MHC type and regardless of previous sensitization (exposure) to the antigen. Our group previously reported the GnT-III transfectant of K562 cells became resistant to NK cells, suggesting that bisecting GlcNAc may play a role in NK cell-mediated cytotoxicity. In contrast to NK cells, cytotoxic T cells contain receptors for the Fc domain of IgG, bind to the Fc portion of an IgG antibody on the surface of target cells such as tumor cells and release cytolytic components that kill the target cell.
Lack of core fucose or addition of bisecting GlcNAc

Effector cells such as Natural Killer cells Mononuclear cells

Target cells such as cancer cells

Fig. 3. Antibody dependent cellular cytotoxicity (ADCC) of IgG1 and the role of bisecting GlcNAc and core fucose (The figure was taken from the courtesy from Dr. M. Sato, Kyowa Hakko Kogyo Co. Ltd.). The addition of bisecting GlcNAc or deletion of core fucose in the Asn 297 in the Fc portion of IgG1 enhances ADCC activity by up to 10-100 fold.

Fig. 2. Positive and negative regulation of MMP genes.
This mechanism of killing is referred to as antibody-dependent cellular cytotoxicity (ADCC) (Fig. 3). A number of mechanisms for the anti-tumor activities of therapeutic antibodies have been proposed and include extended half-life, the blockage of signaling pathways, activation of apoptosis and effector-cell-mediated cytotoxicity. Clynes et al. reported that Fc receptors on effector cells are major components of the in vivo activity of antibodies against tumors. ADCC activity is, therefore, considered to be the major activity in antibody therapy against tumors and it is well known that mouse monoclonal antibodies and humanized antibodies, clinically effective agents such as trastuzumab (Herceptin®) and rituximab (Rituxan®), require both activation via FcγRIII and inhibition via FcγRIIB antibody receptors. Mice that are deficient in activating Fc receptors as well as in the binding of Fc to these receptors were unable to arrest tumor growth in vivo. These results demonstrate that Fc-receptor-dependent mechanisms are substantial contributors to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would preferentially bind to activated Fc receptors and minimally to the inhibitory partner FcγRIIB. Umana et al. reported that the expression of antibodies with altered glycoforms, especially the addition of bisecting GlcNAc leads to an increase in ADCC through a higher affinity for FcγRIII of up to 10-20 fold. They concluded that the increase in ADCC activity is therefore probably due to an increased affinity of the modified antibody for the FcγRIII receptor. A similar study was also independently reported by a Swiss group.

Along a similar line of evidence as described by the above two groups, Shields et al. using Lec13 cells, a variant Chinese hamster ovary cell line, produced human IgG1 that was deficient in the core fucose attached to the Asn 297-linked carbohydrate but was otherwise similar to that produced in normal Chinese hamster ovary cell lines and that from human serum. The lack of fucose on the IgG1 had no effect on its binding to human FcγRI, C1q, or the neonatal Fc receptor. The binding of the fucose-deficient IgG1 to human FcγRIIA was enhanced by up to 50-fold. ADC assays using purified peripheral blood monocytes or NK cells from several donors showed an enhanced cytotoxicity, which was particularly evident at lower antibody concentrations. Independently, Shinkawa et al. reported that the deletion of the core fucose from the IgG1 molecule enhances ADCC activity by up to 50-100 fold. This indicates that the core fucose is an important sugar chain in terms of ADCC activity. Therefore, Fut8 KO mice, which lack the core fucose in glycoproteins, may be useful for the production of various human antibodies against tumor cells. These findings clearly indicate that the α1,6-fucosylation of N-glycans modifies the function of the glycoproteins. The strategy reported by the above reports is applicable to optimizing the ADCC activity of other therapeutic IgGs.

Future perspectives. β1-6 branching GlcNAc produced by GnT-V plays a major role in cancer invasion and metastasis through stabilization of proteases and the angiogenic releasing factor. Bisecting GlcNAc and the core fucose, products of GnT-III and Fut8, respectively, have unique functions in terms of the suppression of cancer metastasis and ADCC activity against cancer and both types of branching sugar chains play a major role in cancer therapy. Gain- and loss-of-functions of various glycosyltransferase could be clarified in all glycosyltransferases identified and so far the real in vivo target proteins can be identified.

Acknowledgements. This work was carried out in collaboration with many scientists, whose names appear in the list of literature citations. The authors sincerely appreciate these contributions and apologize that only a portion of our overall work has been mentioned and many excellent papers published by other groups have not cited due to the limited space. The authors wish to especially acknowledge the faculty staff members, research fellows, graduate students, post-doctoral fellows, research technicians and secretaries in our department. These studies were mainly supported by grants-in aid for the scientific research(s) and the 21 Century COE program supported by the Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology of Japan, respectively.

References
1) Apweiler, R., Hermajokob, H., and Sharon, N. (1999) On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta 473, 4-8.
2) Taniguchi, N., Honke, K., and Fukuda, M. (2001) Handbook of Glycosyltransferases and Related Genes. Springer Tokyo, Tokyo.
3) Hakomori, S. I. (2002) The glycosynapse. Proc. Natl. Acad. Sci. USA 99, 225-232.
4) Moloney, D. J., Panin, V. M., Johnston, S. H., Chen, J., Shao, L., Wilson, R., Wang, Y., Stanley, P., Irvine, K. D., Haltiwanger, R. S., and Vogt, T. F. (2000) Fringe is a glycosyltransferase that
5) Munro, S., and Freeman, M. (2000) The notch signalling regulator fringe acts in the Golgi apparatus and requires the glycosyltransferase signature motif DDX. Curr. Biol. 10, 813-820.

6) Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., Inuzu, T., Mitsushashi, H., Takahashi, S., Takeuchi, M., Herrmann, R., Straub, V., Talim, B., Voit, T., Topaloglu, H., Toda, T., and Endo, T. (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1, 717-724.

7) Schacht, H. (2001) Congenital disorders involving defective N-glycosylation of proteins. Cell Moll. Life Sci. 58, 1085-1104.

8) Freeze, H. (2002) Human disorders in N-glycosylation and animal models. Biochim. Biophys. Acta 1573, 388-393.

9) Love, J. B., and Marth, J. D. (2003) A genetic approach to Mammalian glycan function. Annu. Rev. Biochem. 72, 643-691.

10) Furukawa, K., Takamaya, K., Okada, M., Inoue, M., Fukumoto, S., and Furukawa, K. (2001) Function analysis of complex gangliosides by gangliosides-lacking mutant mice. Biochim. Biophys. Acta 1525, 1-12.

11) Taniguchi, N., Nishikawa, A., Gu, J., Fujii, S., and Taniguchi, N. (1990) A glycomic approach to the identification and characterization of glycoprotein function in cells transfected with glycosyltransferase genes. Proteomics 1, 239-247.

12) Taniguchi, N., and Ikeda, Y. (1998) γ-Glutamyl transpeptidase: catalytic mechanism and gene expression. Adv. Enzymol. Related Areas Mol. Biol. 72, 239-278.

13) Taniguchi, N., Yoshimura, M., Miyoshi, E., Ihara, Y., Nishikawa, A., Kang, R., and Ikeda, Y. (1998) Gene expression and regulation of N-acetylglucosaminyltransferases III and V in cancer tissues. Adv. Enzyme Regul. 38, 223-232.

14) Yamashita, K., Hitoi, A., Taniguchi, N., Yokosawa, N., Tsukada, Y., and Kobata, A. (1983) Comparative study of the sugar chains of γ-glutamyltranspeptidases purified from rat liver and rat AH-66 hepatoma cells. Cancer Res. 43, 5059-5063.

15) Hase, S., Ikenaka, T., and Matsushima, Y. (1981) A highly sensitive method for analyses of sugar moieties of glycoproteins by fluorescence labeling. J. Biochem. 90, 407-414.

16) Taniguchi, N., Nishikawa, A., Fujii, S., and Gu, J. G. (1989) Glycosyltransferase assays using pyridylaminated acceptors: N-acetylglucosaminyltransferase III, IV, and V. Methods Enzymol. 179, 397-408.

17) Nishikawa, A., Gu, J., Fujii, S., and Taniguchi, N. (1990) Determination of N-acetylglucosaminyltransferases III, IV, and V in normal and hepatoma tissues of rats. Biochem. Biophys. Acta 11035, 313-318.

18) Nishikawa, A., Ihara, Y., Hatakeyama, M., Kangawa, K., and Taniguchi, N. (1992) Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine: β-1,4N-acetylglucosaminyltransferase III from rat kidney. J. Biol. Chem. 267, 18199-18204.

19) Barker, R., Olsen, K. W., Shaper, J. H., and Hill, R. L. (1972) Agarose derivatives of uridine diphosphate and N-acetylglucosamine for the purification of a galactosyltransferase. J. Biol. Chem. 247, 7135-7147.

20) Gu, J., Nishikawa, A., Tsuruoka, N., Ohto, M., Yamaguchi, N., Kangawa, K., and Taniguchi, N. (1993) Purification and characterization of UDP-N-acetylglucosamine: α-6-D-mannoside β1-6N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase V) from a human lung cancer cell line. J. Biochem. 113, 614-619.

21) Ihara, Y., Nishikawa, A., Tohma, T., Soejima, H., Niikawa, N., and Taniguchi, N. (1993) cDNA cloning, expression, and chromosomal localization of human N-acetylglucosaminyltransferase III (GnT-III). J. Biochem. 113, 614-619.

22) Oguri, S., Minowa, M. T., Ihara, Y., Taniguchi, N., Ikenaga, H., and Takeuchi, M. (1997) Purification and characterization of UDP-N-acetylglucosamine: α-3-O-mannoside β1-4N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase-IV) from bovine small intestine. J. Biol. Chem. 272, 22721-22727.

23) Taguchi, T., Ogawa, T., Inoue, S., Inoue, Y., Sakamoto, Y., Korekane, H., and Taniguchi, N. (2000) Purification and characterization of UDP-GlcNAc: GlcNAcβ1-6(GlcNAcβ1-2)Manα1-R [GlcNAc to Man]-β1,4-N-acetylglucosaminyltransferase VI from hen oviduct. J. Biol. Chem. 275, 32598-32602.

24) Sakamoto, Y., Taguchi, T., Honke, K., Korekane, H., Watanabe, H., Tano, Y., Dohmae, N., Takio, K., Hori, A., and Taniguchi, N. (2000) Molecular cloning and expression of cDNA encoding chicken UDP-N-acetylβ-D-glucosamine (GlcNAc): GlcNAcβ1-6(GlcNAcβ1-2)Manα1-R [GlcNAc to Man]-β1,4-N-acetylglucosaminyltransferase VI from human oviduct. J. Biol. Chem. 275, 36029-36034.

25) Korekane, H., Taguchi, T., Sakamoto, Y., Honke, K., Dohmae, N., Salminen, H., Toivonen, S., Helin, J., Takio, K., Renkonen, O., and Taniguchi, N. (2003) Purification and cDNA cloning of UDP-GlcNAc:GlcNAcβ1-3Galβ1-4Glc(Nac) to Galβ1,6N-acetylglucosaminyltransferase from rat small intestine: a major carrier of dGnT activity in rat small intestine. Glycobiology 13, 387-400.

26) Uozumi, N., Yanagidani, S., Miyoshi, E., Ihara, Y., Sakuma, T., Gao, C.-X., Teshima, T., Fujii, S., Shiba, T., and Taniguchi, N. (1996) Purification and cDNA cloning of porcine brain GDP-L-Fuc: N-acetylβ-D-glucosaminide α1 → 6fucosyltransferase. J. Biol. Chem. 271, 27810-27817.

27) Yanagidani, S., Uozumi, N., Ihara, Y., Miyoshi, E., Yamaguchi, N., and Taniguchi, N. (1997) Purification and cDNA cloning of GDP-L-Fuc: N-acetylβ-D-glucosaminide α1-6fucosyltransferase (α1-6FucT) from human gastric cancer MKN45 cells. J. Biochem. 126, 626-632.

28) Dennis, J. W., Laferte, S., Wagahorne, C., Breitman, M. L., and Kerbel, R. S. (1987) β1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis.
29) Yamashita, K., Ohkura, T., Tachihana, Y., Takasaki, S., and Kobata, A. (1984) Comparative study of the oligosaccharides released from baby hamster kidney cells and their polyoma transformant by hydrazinolysis. J. Biol. Chem. 259, 10834-10840.

30) Miyoshi, E., Nishikawa, A., Ibara, Y., Gu, J., Sugiyama, T., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. (1993) N-acetylgalactosaminyltransferase III and V messenger RNA levels in LECA rats during hepatocarcinogenesis. Cancer Res. 53, 3899-3902.

31) Miyoshi, E., Ibara, Y., Nishikawa, A., Saito, H., Uozumi, N., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. (1995) Gene expression of N-acetylgalactosaminyltransferases III and V: a possible implication for liver regeneration. Hepatology 22, 1847-1855.

32) Kang, R., Saito, H., Ibara, Y., Miyoshi, E., Koyama, N., Sheng, Y., and Taniguchi, N. (1996) Transcriptional regulation of the N-acetylgalactosaminyltransferase V gene in human biliary duct carcinoma cells (HuCC-T1) is mediated by Ets-1. J. Biol. Chem. 271, 26706-26712.

33) Saito, H., Nishikawa, A., Gu, J., Ibara, Y., Socjima, H., Wada, Y., Sekiya, C., Niikawa, N., and Taniguchi, N. (1994) cDNA cloning and chromosomal mapping of human N-acetylgalactosaminyltransferase V. Biochem. Biophys. Res. Commun. 198, 318-327.

34) Ko, J. H., Miyoshi, E., Noda, K., Ekuni, A., Kang, R., Ikeda, Y., and Taniguchi, N. (1999) Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines. J. Biol. Chem. 274, 22941-22948.

35) Miyoshi, E., Nishikawa, A., Ibara, Y., Saito, H., Uozumi, N., Hayashi, N., Fusamoto, H., Kamada, T., and Taniguchi, N. (1995) Transforming growth factor β up-regulates expression of the N-acetylgalactosaminyltransferase V gene in mouse melanoma cells. J. Biol. Chem. 270, 6216-6220.

36) Chen, L., Zhang, W., Fregien, N., and Pierce, M. (1998) The her-2/neu oncogene stimulates the transcription of N-acetylgalactosaminyltransferase V and expression of its cell surface oligosaccharides products. Oncogene 17, 2087-2093.

37) Yoshimura, M., Ibara, Y., Matsuza, Y., and Taniguchi, N. (1996) Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 271, 13811-13815.

38) Granovsky, M., Fata, J., Pawling, J., Muller, W. J., Khokha, R., and Dennis, J. W. (2000) Suppression of tumor growth and metastasis in Mgtat5-deficient mice. Nature Medicine 6, 306-312.

39) Demetriou, M., Granovsky, M., Quaggin, S., and Dennis, J. W. (2001) Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733-739.

40) Ibara, Y., Miyoshi, E., Ko, J. H., Murata, K., Nakaara, S., Honke, K., Dickson, R. B., Lin, C.-Y., and Taniguchi, N. (2002) Prometastatic effect of N-acetylgalactosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching. J. Biol. Chem. 277, 16960-16967.

41) Ibara, S., Miyoshi, E., Nakahara, S., Sakiyama, H., Ibara, H., Akinaga, A., Honke, K., Dickson, R. B., Lin, C.-Y., and Taniguchi, N. (2004) Addition of β1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin. Glycobiology 14, 139-146.

42) Lin, C.-Y., Anders, J., Johnson, M., Sang, Q. A., and Dickson, R. B. (1999) Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236.

43) Takeuchi, T., Shuman, M. A., and Craik, C. S. (1999) Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061.

44) Santin, A. D., Cane’, S., Bellone, S., Bignetti, E., Palmieri, M., De Las Casas, L. E., Anfossi, S., Roman, J. J., O'Brien, T., and Pecorelli, S. (2003) The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MTSP1) is highly overexpressed in cervical carcinoma. Cancer 98, 1898-1904.

45) Saito, T., Miyoshi, E., Susai, K., Nakano, N., Eguchi, H., Honke, K., and Taniguchi, N. (2002) A secreted type of β1,6-N-acetylgalactosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity. J. Biol. Chem. 277, 17002-17008.

46) Inamori, K., Endo, T., Ide, Y., Fuji, S., Gu, J., Honke, K., and Taniguchi, N. (2003) Molecular cloning and characterization of human GnT-IX, a novel 1,6-N-acetylgalactosaminyltransferase that is specifically expressed in the brain. J. Biol. Chem. 278, 43102-43109.

47) Kaneko, M., Alvarez-Manilla, G., Kumar, M., Lee, I., Lee, J. K., Troupe, K., Zhang, W., Osawa, M., and Pierce, M. (2003) A novel β(1,6)-N-acetylgalactosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity. J. Biol. Chem. 277, 17002-17008.

48) Inamori, K., Endo, T., Gu, J., Matsuo, I., Ito, Y., Fuji, S., Iwasaki, H., Narimatsu, H., Miyoshi, E., Honke, K., and Taniguchi, N. (2003) N-Acetylgalactosaminyltransferase IX acts on the GlcNAc1,2-Man1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. J. Biol. Chem. 278, 2337-2340.

49) Durbeej, M., Sawatzki, S. M., Barresi, R., Schmainda, K. M., Allamand, V., Michele, D. E., and Campbell, K. P. (2003) Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. Proc. Natl. Acad. Sci. USA 100, 8910-8915.

50) Taniguchi, N., and Ibara, Y. (1995) Recent progress in the molecular biology of the cloned N-acetylgalactosaminyltransferases. Glycoconj. J. 12, 733-738.

51) Yoshimura, M., Nishikawa, A., Ibara, Y., Taniguchi, S., and Taniguchi, N. (1995) Suppression of lung metastasis of B16 mouse melanoma by N-acetylgalactosaminyltransferase III gene transfection. Proc. Natl. Acad. Sci. USA 92, 8754-8758.
52) Takeichi, M. (1993) Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol. 5, 806-811.

53) Hirohashi, S. (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153, 333-339.

54) Yoshimura, M., Ibara, Y., Matsuzawa, Y., and Taniguchi, N. (1996). Ablation of E-cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 271, 13811-13815.

55) Kitada, T., Miyoshi, E., Noda, K., Higashiyama, S., Ibara, H., Matsuzawa, N., Hayashi, N., Kawata, S., Matsuzawa, Y., and Taniguchi, N. (2001) The addition of bisecting N-acetylgalactosamine residues to E-cadherin down-regulates the tyrosine phosphorylation of β-catenin. J. Biol. Chem. 276, 475-480.

56) Rebbaa, A., Yamamoto, H., Saito, T., Meuillet, E., Kim, P., Kersey, D. S., Bremer, E. G., Taniguchi, N., and Moskal, J. R. (1997) Gene transfection-mediated overexpression of β1,4-N-acetylgalactosamine bisecting oligosaccharides in glioma cell line 1373 MG inhibits epidermal growth factor receptor function. J. Biol. Chem. 272, 9275-9279.

57) Sato, Y., Takahashi, M., Shibukawa, Y., Jain, S. K., Hamaoka, R., Miyagawa, J., Yaginuma, Y., Honke, K., Ishikawa, M., and Taniguchi, N. (2001) Overexpression of N-acetylgalactosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors. J. Biol. Chem. 276, 11956-11962.

58) Ibara, Y., Sakamoto, Y., Mihara, M., Shimizu, K., and Taniguchi, N. (1997) Overexpression of N-acetylgalactosaminyltransferase III disrupts the tyrosine phosphorylation of Trk with resultant signaling dysfunction in PC12 cells treated with nerve growth factor. J. Biol. Chem. 272, 9029-9034.

59) Tsuda, T., Ikeda, Y., and Taniguchi, N. (2000) The Asn-420-residue of glycopeptide from N-acetylgalactosaminyltransferase III-transfected HeLaS3 cells. J. Biol. Chem. 276, 3197-3203.

60) Wilson, J. R., Williams, D., and Schachter, H. (1976) The control of glycoprotein synthesis: N-acetylgalactosamine linkage to a mannose residue as a signal for the attachment of L-fucose to the asparagine-linked N-acetylgalactosamine residue of glycopeptide from ε1-acid glycoprotein. Biochem. Biophys. Res. Commun. 72, 909-916.

61) Hoyle, G. W., Li, J., Finkelstein, J. B., Eisenberg, T., Liu, J. Y., Laskey, J. A., Athas, G., Morris, G. F., and Brody, A. R. (1999) Ephrseymsomatous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am. J. Pathol. 154, 1763-1775.

62) D’Armiento, J., Dalal, S. S., Okada, Y., Berg, R. A., and Chada, K. (1992) Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71, 955-961.

63) Shiomi, T., Okada, Y., Foronyj, R., Schiltz, J., Jaenish, R., Krane, S., and D’Armiento, J. (2003) Ephrsemyostat changes are caused by degradation of type III collagen in transgenic mice expressing MMP-1. Exp. Lung Res. 29, 1-15.

65) Zheng, T., Zhu, Z., Wang, Z., Homer, R. J., Ma, B., Riese, R. J., Jr, Chapman, H. A. Jr, Shapiro, S. D., and Elias, J. A. (2000) Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-9 and cathepsin-dependent emphysema. J. Clin. Invest. 106, 1081-1093.

66) Morris, D. G., Huang, X., Kaninski, N., Wang, Y., Shapiro, S. D., Delgano, G., Glick, A., and Sheppard, D. (2003) Loss of integrin α(v)β6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 422, 160-173.

67) Wang, Z., Zheng, T., Zhu, Z., Homer, R. J., Riese, R. J., Chapman, H. A. Jr, Shapiro, S. D., and Elias, J. A. (2000) Interferon gamma induction of pulmonary emphysema in the adult murine lung. J. Exp. Med. 192, 1587-1600.

68) Fujita, M., Shannon, J. M., Irvin, C. G., Fagan, K. A., Cool, C., Augustin, A., and Mason, R. J. (2001) Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 280, L39-L49.

69) Yuan, W., and Varga, J. (2001) Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J. Biol. Chem. 276, 38502-38510.

70) Yoshimura, M., Ibara, Y., Ohnishi, A., Ijuhin, N., Nishimura, T., Kanakura, Y., Matsuzawa, Y., and Taniguchi, N. (1996) Bisecting N-acetylgalactosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res. 56, 412-418.

71) Casadevall, A., and Pirofski, L. A. (2003) Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 9, 474-478.

72) Clynes, R. A., Towers, T. L., Presta, L. G., and Ravetch, J. V. (2000) Inhibitory Fc receptors mediate in vivo cytotoxicity against tumor targets. Nature Med. 6, 373-374.

73) Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H., and Bailey, J. E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol. 17, 176-180.

74) Davies, J., Jiang, L., Pan, L. Z., LaBarre, M. J., Anderson, D., and Reff, M. (2001) Expression of GmTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol. Bioeng. 74, 288-294.

75) Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Studlen, A., Li, B., Fox, J. A., and Presta, L. G. (2001) High resolution mapping of the binding site on human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn
and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604.

76) Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylgalactosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473.